Clinical trials
catalyst calendar across sponsors →Studies where FBRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 7 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +2 more) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.NCT07205159Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: FB102, Placebo | Alopecia Areata | 32 | 2027-03-10 | in 202 d | 2025-11-20 |
| Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac DiseaseNCT06982963Change from baseline in the VCIELRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Biological: FB102 · Other: Placebo | Celiac Disease | 100 | 2027-02-28 | in 192 d | 2025-11-18 |
| A Study Testing the Safety and Effects of FB102 in Healthy VolunteersNCT07623057Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: FB102 Single dose, FB102 Multiple doses, FB102 Placebo | Healthy Volunteer | 48 | Feb 2027 | ≤ 192 d | 2026-08-19 |
| A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental VitiligoNCT06905873Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: FB102, Placebo | Vitiligo | 64 | 2026-12-31 | in 133 d | 2025-11-20 |
| Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 StudyNCT04936113Number of adverse eventsOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Failure of the Phase 2 study (protocol FB401-01) to meet its endpoint. | Biological: FB-401 | Atopic Dermatitis | 36 | 2021-09-30actual | — | 2021-10-28 |
| Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisNCT04504279EASI 50Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: FB-401, Placebo | Atopic Dermatitis | 154 | 2021-07-14actual | — | 2021-09-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19